Which has better earnings & valuation, WGS or HNGE?

GeneDx has higher earnings, but lower revenue than Hinge Health. GeneDx is trading at a lower price-to-earnings ratio than Hinge Health, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio GeneDx $427.54M 5.95 -$21.02M -$3.64 N/A Hinge Health $587.86M 12.20 -$528.26M $1.28 69.42

Is WGS or HNGE more profitable?

Hinge Health has a net margin of 15.15% compared to GeneDx's net margin of -23.41%. Hinge Health's return on equity of 51.60% beat GeneDx's return on equity. Company Net Margins Return on Equity Return on Assets GeneDx -23.41% 4.12% 2.26% Hinge Health 15.15% 51.60% 14.16%

Does the media favor WGS or HNGE?

In the previous week, Hinge Health had 3 more articles in the media than GeneDx. MarketBeat recorded 11 mentions for Hinge Health and 8 mentions for GeneDx. GeneDx's average media sentiment score of 0.90 beat Hinge Health's score of 0.37 indicating that GeneDx is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GeneDx 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Hinge Health 6 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings & valuation, CHE or WGS?

Chemed has higher revenue and earnings than GeneDx. GeneDx is trading at a lower price-to-earnings ratio than Chemed, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Chemed $2.53B 2.66 $265.24M $19.91 25.87 GeneDx $427.54M 5.95 -$21.02M -$3.64 N/A

Is CHE or WGS more profitable?

Chemed has a net margin of 10.60% compared to GeneDx's net margin of -23.41%. Chemed's return on equity of 31.77% beat GeneDx's return on equity. Company Net Margins Return on Equity Return on Assets Chemed 10.60% 31.77% 18.90% GeneDx -23.41% 4.12% 2.26%

Does the media favor CHE or WGS?

In the previous week, Chemed and Chemed both had 8 articles in the media. Chemed's average media sentiment score of 1.09 beat GeneDx's score of 0.90 indicating that Chemed is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Chemed 5 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive GeneDx 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings & valuation, WGS or HIMS?

Hims & Hers Health has higher revenue and earnings than GeneDx. Hims & Hers Health is trading at a lower price-to-earnings ratio than GeneDx, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio GeneDx $427.54M 5.95 -$21.02M -$3.64 N/A Hims & Hers Health $2.35B 2.73 $128.37M -$0.63 N/A

Does the media prefer WGS or HIMS?

In the previous week, Hims & Hers Health had 24 more articles in the media than GeneDx. MarketBeat recorded 32 mentions for Hims & Hers Health and 8 mentions for GeneDx. GeneDx's average media sentiment score of 0.90 beat Hims & Hers Health's score of 0.17 indicating that GeneDx is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GeneDx 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Hims & Hers Health 2 Very Positive mention(s) 5 Positive mention(s) 23 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher earnings and valuation, RDNT or WGS?

RadNet has higher revenue and earnings than GeneDx. RadNet is trading at a lower price-to-earnings ratio than GeneDx, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio RadNet $2.04B 2.91 -$18.65M -$0.27 N/A GeneDx $427.54M 5.95 -$21.02M -$3.64 N/A

Is RDNT or WGS more profitable?

RadNet has a net margin of -0.93% compared to GeneDx's net margin of -23.41%. GeneDx's return on equity of 4.12% beat RadNet's return on equity. Company Net Margins Return on Equity Return on Assets RadNet -0.93% 2.61% 0.91% GeneDx -23.41% 4.12% 2.26%

Does the media refer more to RDNT or WGS?

In the previous week, RadNet and RadNet both had 8 articles in the media. GeneDx's average media sentiment score of 0.90 beat RadNet's score of 0.55 indicating that GeneDx is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment RadNet 2 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive GeneDx 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer WGS or LFST?

In the previous week, LifeStance Health Group had 9 more articles in the media than GeneDx. MarketBeat recorded 17 mentions for LifeStance Health Group and 8 mentions for GeneDx. GeneDx's average media sentiment score of 0.90 beat LifeStance Health Group's score of 0.89 indicating that GeneDx is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GeneDx 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive LifeStance Health Group 7 Very Positive mention(s) 1 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

GeneDx (WGS) Competitors

$85.26 +1.30 (+1.55%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$85.50 +0.24 (+0.28%)

As of 09/11/2026 07:30 PM Eastern

Compare

WGS vs. HNGE, CHE, HIMS, RDNT, and LFST

Should you buy GeneDx stock or one of its competitors? GeneDx's main competitors and comparable companies include Hinge Health (HNGE), Chemed (CHE), Hims & Hers Health (HIMS), RadNet (RDNT), and LifeStance Health Group (LFST). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare services" industry.

How does GeneDx compare to Hinge Health?

GeneDx (NASDAQ:WGS) and Hinge Health (NYSE:HNGE) are both mid-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, dividends, earnings, media sentiment, risk and profitability.

61.7% of GeneDx shares are held by institutional investors. 25.2% of GeneDx shares are held by company insiders. Comparatively, 18.9% of Hinge Health shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

GeneDx has a beta of 1.99, indicating that its share price is 99% more volatile than the broader market. Comparatively, Hinge Health has a beta of 1.38, indicating that its share price is 38% more volatile than the broader market.

In the previous week, Hinge Health had 3 more articles in the media than GeneDx. MarketBeat recorded 11 mentions for Hinge Health and 8 mentions for GeneDx. GeneDx's average media sentiment score of 0.90 beat Hinge Health's score of 0.37 indicating that GeneDx is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GeneDx	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Hinge Health	6 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

GeneDx presently has a consensus target price of $89.57, suggesting a potential upside of 5.06%. Hinge Health has a consensus target price of $101.93, suggesting a potential upside of 14.71%. Given Hinge Health's higher probable upside, analysts plainly believe Hinge Health is more favorable than GeneDx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GeneDx	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89
Hinge Health	1 Sell rating(s)	2 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.83

GeneDx has higher earnings, but lower revenue than Hinge Health. GeneDx is trading at a lower price-to-earnings ratio than Hinge Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GeneDx	$427.54M	5.95	-$21.02M	-$3.64	N/A
Hinge Health	$587.86M	12.20	-$528.26M	$1.28	69.42

Hinge Health has a net margin of 15.15% compared to GeneDx's net margin of -23.41%. Hinge Health's return on equity of 51.60% beat GeneDx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GeneDx	-23.41%	4.12%	2.26%
Hinge Health	15.15%	51.60%	14.16%

Summary

Hinge Health beats GeneDx on 10 of the 16 factors compared between the two stocks.

How does GeneDx compare to Chemed?

Chemed (NYSE:CHE) and GeneDx (NASDAQ:WGS) are both mid-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, media sentiment, analyst recommendations, profitability, institutional ownership and valuation.

Chemed has a beta of 0.51, suggesting that its stock price is 49% less volatile than the broader market. Comparatively, GeneDx has a beta of 1.99, suggesting that its stock price is 99% more volatile than the broader market.

Chemed has a net margin of 10.60% compared to GeneDx's net margin of -23.41%. Chemed's return on equity of 31.77% beat GeneDx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Chemed	10.60%	31.77%	18.90%
GeneDx	-23.41%	4.12%	2.26%

Chemed presently has a consensus price target of $530.75, indicating a potential upside of 3.02%. GeneDx has a consensus price target of $89.57, indicating a potential upside of 5.06%. Given GeneDx's stronger consensus rating and higher possible upside, analysts clearly believe GeneDx is more favorable than Chemed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Chemed	0 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.17
GeneDx	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89

Chemed has higher revenue and earnings than GeneDx. GeneDx is trading at a lower price-to-earnings ratio than Chemed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Chemed	$2.53B	2.66	$265.24M	$19.91	25.87
GeneDx	$427.54M	5.95	-$21.02M	-$3.64	N/A

95.9% of Chemed shares are held by institutional investors. Comparatively, 61.7% of GeneDx shares are held by institutional investors. 3.3% of Chemed shares are held by company insiders. Comparatively, 25.2% of GeneDx shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Chemed and Chemed both had 8 articles in the media. Chemed's average media sentiment score of 1.09 beat GeneDx's score of 0.90 indicating that Chemed is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Chemed	5 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
GeneDx	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Chemed beats GeneDx on 9 of the 16 factors compared between the two stocks.

How does GeneDx compare to Hims & Hers Health?

GeneDx (NASDAQ:WGS) and Hims & Hers Health (NYSE:HIMS) are both mid-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, dividends, earnings, profitability, risk and valuation.

61.7% of GeneDx shares are held by institutional investors. Comparatively, 63.5% of Hims & Hers Health shares are held by institutional investors. 25.2% of GeneDx shares are held by insiders. Comparatively, 11.8% of Hims & Hers Health shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Hims & Hers Health has a net margin of -5.51% compared to GeneDx's net margin of -23.41%. GeneDx's return on equity of 4.12% beat Hims & Hers Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GeneDx	-23.41%	4.12%	2.26%
Hims & Hers Health	-5.51%	-6.51%	-1.20%

GeneDx currently has a consensus price target of $89.57, suggesting a potential upside of 5.06%. Hims & Hers Health has a consensus price target of $32.43, suggesting a potential upside of 18.18%. Given Hims & Hers Health's higher probable upside, analysts plainly believe Hims & Hers Health is more favorable than GeneDx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GeneDx	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89
Hims & Hers Health	1 Sell rating(s)	12 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.13

In the previous week, Hims & Hers Health had 24 more articles in the media than GeneDx. MarketBeat recorded 32 mentions for Hims & Hers Health and 8 mentions for GeneDx. GeneDx's average media sentiment score of 0.90 beat Hims & Hers Health's score of 0.17 indicating that GeneDx is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GeneDx	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Hims & Hers Health	2 Very Positive mention(s)	5 Positive mention(s)	23 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

GeneDx has a beta of 1.99, suggesting that its share price is 99% more volatile than the broader market. Comparatively, Hims & Hers Health has a beta of 2.42, suggesting that its share price is 142% more volatile than the broader market.

Hims & Hers Health has higher revenue and earnings than GeneDx. Hims & Hers Health is trading at a lower price-to-earnings ratio than GeneDx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GeneDx	$427.54M	5.95	-$21.02M	-$3.64	N/A
Hims & Hers Health	$2.35B	2.73	$128.37M	-$0.63	N/A

Summary

GeneDx beats Hims & Hers Health on 9 of the 17 factors compared between the two stocks.

How does GeneDx compare to RadNet?

RadNet (NASDAQ:RDNT) and GeneDx (NASDAQ:WGS) are both mid-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, profitability, risk, analyst recommendations, institutional ownership and media sentiment.

77.9% of RadNet shares are owned by institutional investors. Comparatively, 61.7% of GeneDx shares are owned by institutional investors. 5.1% of RadNet shares are owned by company insiders. Comparatively, 25.2% of GeneDx shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

RadNet currently has a consensus price target of $90.00, indicating a potential upside of 19.22%. GeneDx has a consensus price target of $89.57, indicating a potential upside of 5.06%. Given RadNet's higher probable upside, equities research analysts clearly believe RadNet is more favorable than GeneDx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RadNet	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.89
GeneDx	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89

RadNet has a net margin of -0.93% compared to GeneDx's net margin of -23.41%. GeneDx's return on equity of 4.12% beat RadNet's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
RadNet	-0.93%	2.61%	0.91%
GeneDx	-23.41%	4.12%	2.26%

RadNet has higher revenue and earnings than GeneDx. RadNet is trading at a lower price-to-earnings ratio than GeneDx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
RadNet	$2.04B	2.91	-$18.65M	-$0.27	N/A
GeneDx	$427.54M	5.95	-$21.02M	-$3.64	N/A

RadNet has a beta of 1.41, meaning that its stock price is 41% more volatile than the broader market. Comparatively, GeneDx has a beta of 1.99, meaning that its stock price is 99% more volatile than the broader market.

In the previous week, RadNet and RadNet both had 8 articles in the media. GeneDx's average media sentiment score of 0.90 beat RadNet's score of 0.55 indicating that GeneDx is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
RadNet	2 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
GeneDx	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

GeneDx beats RadNet on 8 of the 15 factors compared between the two stocks.

How does GeneDx compare to LifeStance Health Group?

GeneDx (NASDAQ:WGS) and LifeStance Health Group (NASDAQ:LFST) are both mid-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, profitability, dividends, analyst recommendations, valuation, institutional ownership and media sentiment.

GeneDx has a beta of 1.99, meaning that its share price is 99% more volatile than the broader market. Comparatively, LifeStance Health Group has a beta of 1.22, meaning that its share price is 22% more volatile than the broader market.

LifeStance Health Group has higher revenue and earnings than GeneDx. GeneDx is trading at a lower price-to-earnings ratio than LifeStance Health Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GeneDx	$427.54M	5.95	-$21.02M	-$3.64	N/A
LifeStance Health Group	$1.42B	3.48	$9.66M	$0.13	99.77

LifeStance Health Group has a net margin of 3.19% compared to GeneDx's net margin of -23.41%. GeneDx's return on equity of 4.12% beat LifeStance Health Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GeneDx	-23.41%	4.12%	2.26%
LifeStance Health Group	3.19%	3.39%	2.33%

61.7% of GeneDx shares are owned by institutional investors. Comparatively, 85.5% of LifeStance Health Group shares are owned by institutional investors. 25.2% of GeneDx shares are owned by insiders. Comparatively, 3.5% of LifeStance Health Group shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, LifeStance Health Group had 9 more articles in the media than GeneDx. MarketBeat recorded 17 mentions for LifeStance Health Group and 8 mentions for GeneDx. GeneDx's average media sentiment score of 0.90 beat LifeStance Health Group's score of 0.89 indicating that GeneDx is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GeneDx	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
LifeStance Health Group	7 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

GeneDx presently has a consensus price target of $89.57, indicating a potential upside of 5.06%. LifeStance Health Group has a consensus price target of $12.88, indicating a potential downside of 0.73%. Given GeneDx's stronger consensus rating and higher possible upside, analysts clearly believe GeneDx is more favorable than LifeStance Health Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GeneDx	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89
LifeStance Health Group	0 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.73

Summary

GeneDx and LifeStance Health Group tied by winning 8 of the 16 factors compared between the two stocks.

Get GeneDx News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding WGS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

WGS vs. The Competition

Export

Metric	GeneDx	Healthcare Providers & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.54B	$9.84B	$7.17B	$12.85B
Dividend Yield	N/A	2.61%	2.57%	11.71%
P/E Ratio	-23.42	33.53	274.94	25.33
Price / Sales	5.95	4.89	685.45	111.12
Price / Cash	37.20	125.15	76.65	51.52
Price / Book	8.09	5.29	10.33	6.20
Net Income	-$21.02M	$313.25M	$3.50B	$358.50M
7 Day Performance	-0.85%	-1.26%	-3.32%	-2.35%
1 Month Performance	3.48%	-0.98%	-0.41%	-2.77%
1 Year Performance	-31.21%	15.13%	19.21%	7.63%

GeneDx Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
WGS GeneDx	1.8029 of 5 stars	$85.26 +1.5%	$89.57 +5.1%	-32.3%	$2.54B	$427.54M	N/A	1,300	News Coverage Insider Trade
HNGE Hinge Health	3.5948 of 5 stars	$88.32 -4.7%	$101.93 +15.4%	+48.0%	$7.48B	$587.86M	71.56	1,437	News Coverage Analyst Forecast Insider Trade
CHE Chemed	4.4122 of 5 stars	$517.08 -0.4%	$530.75 +2.6%	+12.5%	$6.78B	$2.53B	26.02	15,811	Positive News
HIMS Hims & Hers Health	2.7106 of 5 stars	$27.21 -3.4%	$32.50 +19.4%	-47.0%	$6.57B	$2.35B	N/A	2,442	Trending News Analyst Forecast
RDNT RadNet	3.1668 of 5 stars	$70.75 -0.2%	$90.00 +27.2%	+2.4%	$5.58B	$2.04B	N/A	11,264	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:WGS) was last updated on 9/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

GeneDx (WGS) Competitors